$1.46+0.03 (+2.10%)
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Dogwood Therapeutics, Inc. in the Healthcare sector is trading at $1.46. The stock is currently near its 52-week low of $1.28, remaining 66.0% below its 200-day moving average. Technical signals show oversold RSI of 26 and bullish MACD crossover, explaining why DWTX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has ...
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Dogwood Therapeutics, Inc. is one of the oversold biotech stocks on this list. TheFly reported on April 15 that DWTX announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for SP16, an intravenous candidate being […]
Dogwood Therapeutics (DWTX) said Monday that an interim analysis of its Phase 2b study for Halneuron
US equity futures were higher pre-bell Monday as traders appeared to brush off concerns over a poten